Table 2 A table showing percentages of adverse events for the MDR-TB patients on second line anti-TB drugs
Adverse Events | Mild | Moderate | Severe | Life threatening | Total |
|---|---|---|---|---|---|
Arthralgia | 204 (83.6%) | 38 (15.57%) | 2 (0.8%) | (29%) 244/856 | |
Peripheral Neuropathy | 22 (75.9%) | 6 (20.7%) | 1 (3.4%) | (3%) 29/856 | |
Gynecomastia | 5 (71.4%) | 2 (28.6%) | (1%) 7/856 | ||
Dermatologic | 12 (33.3%) | 22 (61.1%) | 2 (5.5%) | (4%) 36/856 | |
Ototoxicity | 19 (25.3%) | 18 (24%) | 24 (32%) | 14 (18.7%) | (9%) 75/856 |
Gastrointestinal | 14 (37.8%) | 22 (59.4%) | 1 (2.7%) | (4%) 37/856 | |
Hypothyroidism | 6 (100%) | (1%) 6/856 | |||
Hepatotoxicity | 1 (100%) | (0.1%) 1/856 | |||
Nausea / Vomiting | 17 (29.3%) | 37 (63.8%) | 4 (6.9%) | (7%) 58/856 | |
Psychiatric / psychosis | 5 (33.3%) | 4 (26.7%) | 6 (40%) | (2%) 15/856 | |
Vision change | 14 (82.3%) | 2 (11.8%) | 1 (5.8%) | (2%) 17/856 |